14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.72 $7.24 Wednesday, 24th Apr 2024 AFMD stock ended at $4.88. This is 8.79% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 11.72% from a day low at $4.87 to a day high of $5.44.
90 days $4.25 $7.24
52 weeks $2.24 $11.10

Historical Affimed N.V. prices

Date Open High Low Close Volume
Oct 27, 2021 $67.50 $68.39 $63.85 $65.80 141 038
Oct 26, 2021 $62.40 $67.10 $61.90 $66.90 322 557
Oct 25, 2021 $59.70 $62.00 $59.20 $61.90 90 342
Oct 22, 2021 $61.20 $61.25 $57.85 $59.90 69 700
Oct 21, 2021 $61.50 $63.20 $61.20 $61.50 61 704
Oct 20, 2021 $60.10 $61.70 $59.75 $60.70 54 456
Oct 19, 2021 $58.80 $61.40 $58.50 $59.70 80 194
Oct 18, 2021 $59.10 $59.40 $57.25 $58.30 72 477
Oct 15, 2021 $60.50 $60.80 $58.90 $59.10 49 472
Oct 14, 2021 $59.10 $60.25 $58.55 $59.40 42 883
Oct 13, 2021 $59.60 $60.50 $58.25 $58.50 48 580
Oct 12, 2021 $58.10 $59.75 $57.90 $58.90 41 198
Oct 11, 2021 $56.50 $59.30 $56.10 $58.10 65 821
Oct 08, 2021 $59.50 $59.50 $56.30 $57.00 94 589
Oct 07, 2021 $57.00 $59.40 $56.50 $59.40 68 666
Oct 06, 2021 $57.10 $58.20 $56.30 $56.90 52 853
Oct 05, 2021 $58.60 $59.30 $57.00 $57.60 68 270
Oct 04, 2021 $61.00 $61.00 $58.20 $58.40 69 982
Oct 01, 2021 $62.60 $62.70 $58.60 $61.60 108 643
Sep 30, 2021 $60.70 $63.50 $59.55 $61.80 138 602
Sep 29, 2021 $60.90 $61.50 $58.00 $58.50 61 255
Sep 28, 2021 $61.90 $62.30 $59.90 $60.50 84 042
Sep 27, 2021 $62.10 $64.10 $61.10 $62.20 84 307
Sep 24, 2021 $65.40 $65.40 $62.10 $62.60 60 326
Sep 23, 2021 $64.00 $66.00 $63.50 $65.90 45 525
Click to get the best stock tips daily for free!

About Affimed N.V.

Affimed N.V. Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispec... AFMD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT